For the adjunctive treatment of oral inflammatory and ulcerative lesions

**Sticktoitiveness**

**Oralone**® adheres to oral lesions providing targeted anti-inflammatory therapy

Oralone® (Triamcinolone Acetonide Dental Paste USP, 0.1%) is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. The following local adverse reactions may occur with corticosteroid-containing dental pastes: burning, itching, irritation, dryness, blistering or peeling not present prior to therapy, perioral dermatitis, allergic contact dermatitis, maceration of the oral mucosa, secondary infection, and atrophy of the oral mucosa. Oralone® is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat. Oralone® may cause local adverse reactions. If irritation develops, Oralone® should be discontinued and appropriate therapy instituted.

See package insert for full prescribing information.
Sticktoitiveness
– what it means for you and your patients

Lesion adhesion
■ Oralone’s muco-adhesive base facilitates targeted delivery of Triamcinalone Acetonide. Early initiation of treatment may result in a more rapid response 3

Sticking around
■ Triamcinolone Acetonide Dental Paste USP 0.1% was first approved by the FDA in 1960 (Kenalog in Orabase®)—meaning it has a track record of nearly 50 years 4

A value proposition sure to stick
■ Taro is the sole manufacturer of Oralone® and its generic, so patients can receive brand-quality treatment at a generic price

*Oralone® is equivalent to Kenalog in Orabase®, which is no longer available.

References: